Review: Cutaneous Malignant Melanoma

References

• Ringborg U, Afzelius L-E, Lagerlöf B, Adami H-O, Augustsson I, Blomqvist E, Boeryd B, Carlin E, Ed-Strom S, Eldh J, Hanner P, Hansson J, Johansson H, Ch Lindholm, Malec E, Naslund L, Schnürer L B, Sköld S, Wersåll J. Cutaneous malignant melanoma of the head and neck. Analysis of treatment results and prognostic factors in 581 patients: A report from the Swedish Melanoma Study Group. Cancer 1993; 71: 751–8
   PubMed Web of Science ®Google Scholar
• Thörn M, Bergström R, Adami H-O, Ringborg U. Trends in incidence of malignant melanoma in Sweden by anatomic site 1960-1984. Am J Epidemiol 1990; 132: 1066–77
   PubMed Web of Science ®Google Scholar
• van der Esch E P, Muir C S, Nectous J, Marfalane G, Maisonneuve P, Bharucha H, Briggs J, Cooke R A, Dempster A G, Essex W B, Hofer P A, Hood A F, Ironside P, Larsen T E, Little J H, Philips R, Pfau R S, Prade M, Pozharisski K M, Rilke F, Shaffler K. Temporal change in diagnostic criteria as a cause of the increase of malignant melanoma over time is unlikely. Int J Cancer 1991; 47: 483–90
   PubMed Web of Science ®Google Scholar
• Ragnarsson-Olding B, Johansson H, Rutqvist L E, Ringborg U. Malignant melanoma of the vulva and vagina: Trends in incidence, age distribution and long-term survival among 245 consecutive cases in Sweden 1960-1985. Cancer 1993; 71: 1893–75
   PubMed Web of Science ®Google Scholar
• Thörn M, Adami H-O, Bergström R, Ringborg U, Krusemo U-B. Trends in survival from malignant melanoma: Remarkable improvement in 23 years. J Natl Cancer Inst 1989; 81: 611–7
   PubMedGoogle Scholar
• Armstrong BK. Melanoma of the skin. Br Med Bull 1984; 40: 346–50
   PubMed Web of Science ®Google Scholar
• Dobson A J, Leeder SR. Mortality from malignant melanoma in Australia-effects due to country of birth. Int J Epidemiol 1982; 11: 207–11
   PubMed Web of Science ®Google Scholar
• Holman C DJ, Armstrong BK. Cutaneous malignant melanoma and indicators of total accumulated exposure to the sun: an analysis separating histogenetic types. J Natl Cancer Inst 1984; 73: 75–82
   PubMed Web of Science ®Google Scholar
• Rivers J K, MacLennan R, Kelly J W, Lewis A E, Tate B J, Harrison S, McCarthy WH. The Eastern Australian childhood nevus study: Prevalence of atypical nevi, congenital nevus-like nevi, and other pigmented lesions. J Am Acad Dermatol 1995; 32: 957–63
   PubMed Web of Science ®Google Scholar
• Scheibner A, Milton G W, McCarthy W H, Nordlund J J, Pearson LI. Multiple primary melanoma-a review of 98 cases. Australas J Dermatol 1982; 23: 1–8
   PubMedGoogle Scholar
• Greene M H, Clark WH, Jr, Tucker M A, Kraemer K H, Elder D E, Fraser MC. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985; 102: 458–65
   PubMed Web of Science ®Google Scholar
• Bale S J, Dracopoli N C, Tucker M A, Clark W H, Fraser M C, Stanger B Z, Green P, Donis-Keller H, Housman D E, Greene MH. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome lp. N Engl J Med 1989; 320: 1367–72
   PubMed Web of Science ®Google Scholar
• Kamb A, Gruis N A, Weaver-Feldhaus J, Liu Q, Harsh-Man K, Tavtigian S V, Stockert E, Day RS, III, Jonsson B E, Skoinick MH. Cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436–40
   PubMed Web of Science ®Google Scholar
• Platz A, Sevigny P, Norberg T, Ring P, Lagerlof B, Ringborg U. Genes involved in cell cycle Gl checkpoint control are frequently mutated in human melanoma metastases. Br J Cancer, in press
   Web of Science ®Google Scholar
• Platz A, Ringborg U, Mansson-Brahme E, Lagerldf B. Melanoma metastases from patients with hereditary cutaneous malignant melanoma contain a high frequency of N-ras activating mutations. Melanoma Res 1994; 4: 169–77
   PubMed Web of Science ®Google Scholar
• Clark WH, Jr. Tumor progression and the nature of cancer. Br J Cancer 1991; 64: 631–44
   PubMed Web of Science ®Google Scholar
• Balch C M, Cascinelli N, Drzewiecki K T, Eldh J, MacKie R N, McCarthy W H, McLeod G R, Morton D L, Seigler H F, Shaw H M, Sim F H, Sober A J, Soong S-J, Take-Matsu H, Tonak J, Wong J. A comparison of prognostic factors worldwide. Cutaneous Melanoma. 2nd edn., C HM Balch, A N Houghten, G W Milton, A J Sober, S-J Soong. JB Lippincott Co, Philadelphia 1992; 188–99
   Google Scholar
• Urist M M, Balch C M, Soong S-J, Milton G W, Shaw H M, McGovern V J, Murad T M, McCarthy W H, Mad-Dox WA. Head and neck melanoma in 534 clinical stage I patients. A prognostic factors analysis and results of surgical treatment. Ann Surg 1984; 200: 769–75
   PubMed Web of Science ®Google Scholar
• Månsson-Brahme E., Carstensen J, Erhardt K, Lagerlöf B, Ringborg U, Rutqvist LE. Prognostic factors in thin cutaneous malignant melanoma. Cancer 1994; 73: 2324–32
   PubMed Web of Science ®Google Scholar
• Veronesi U, Cascinelli N, Adamus J, Balch C H, Bandlera D, Barschuk A, Bufalino R, Craig P, De Marsillac J, Durand J C, van Geel A N, Holmström H, Hunter J A, Jörgensen O G, Kiss B, Kroon B, Lacour J, Lejeune F, MacKie R, Mechl Z, Mitrov G, Morabito A, Nosek H, Panizzon R, Prade M, Santi P L, van Slooten E, Tomin R, Trapeznikov N, Tsanov T, Urist M, Wozniak KD. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of I or 3 cm. N Engl J Med 1988; 318: 1159–62
   PubMed Web of Science ®Google Scholar
• Ringborg U, Andersson R, Eldh J, Glaumann B, Haf-ström L O, Jacobsson S, Jonsson P-E, Johansson H, Krysander L, Lagerlöf B. The Swedish Group Melanoma Study Resection margins of 2 versus 5 cm in cutaneous malignant melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 1996; 77: 1809–14
   PubMed Web of Science ®Google Scholar
• Hansson J, Ringborg U, Lagerlöf B, Afzelius L-E, Augustsson I, Blomqvist E, Boeryd B, Carlin E, Edström S, Eldh J, Hanner P, Hedenborg L, Hofter P-A, Johansson H, Lindholm C, Malec E, Näslund L, Schnürer L B, Sköld S, Wersäll P. Elective lymph node dissection in stage I cutaneous malignant melanoma of the head and neck. A report from the Swedish Melanoma Study Group. Melanoma Res 1994; 4: 407–11
   PubMed Web of Science ®Google Scholar
• Kirkwood J M, Hunt Strawderman M, Ernstoff M S, Smith T J, Borden EC. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial EST 1684. J Clin Oncol 1996; 14: 7–17
   PubMed Web of Science ®Google Scholar
• Hafström L O, Rudenstam C-M, Blomqvist E, Ch Ingvar, Jonsson P-E, Lagerlöf B, Ch Lindohlm, Ringborg U, Westman G, Östrup L. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. J Clin Oncol 1991; 9: 2091–4
   PubMed Web of Science ®Google Scholar
• Herd R M, Cooper E J, Hunter J AA, McLaren K, Chetty U, Watson A CH, Gollock J. Cutaneous malignant melanoma. Publicity, screening clinics and survival-the Edinburgh experience 1982-90. Br J Dermatol 1995; 132: 563–70
   PubMed Web of Science ®Google Scholar